Increased Tregs either showed a trend toward association or were significantly associated with poor response and inferior OS, especially in frontline patients (supplemental Figure 5).
← all excerpts
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.
1
—
—